Protocol Ledger

NCT06819891 · Phase III · RECRUITING

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Interventional Phase III clinical trial protocol NCT06819891 sponsored by Roche / Genentech in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-12 Enrollment: 425 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06819891
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)425 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06819891
Protocol FieldVerified Registry Value
NCT IdentifierNCT06819891
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment425 participants (ESTIMATED)
Registered Start Date2025-05-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06819891
Hospital Research SiteLocationSite Profile
Om Research LLCLancaster, CAOpen Hospital Dossier ->
Empire Clinical ResearchPomona, CAOpen Hospital Dossier ->
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI